Business Context and Reporting Period
Company: Prothena Corporation plc (PRTA)
Filing Type: Form 8-K (Current Report)
Date of Report: May 24, 2024
Event: Entry into a Material Definitive Agreement and expiration of the research term under the Master Collaboration Agreement with Bristol Myers Squibb (BMS).
Key Financial Metrics and Agreement Terms
This filing details a new Global License Agreement regarding the PRX019 research program. Key financial terms include:
- Upfront Payment: $80 million paid by BMS to Prothena.
- Development and Regulatory Milestones: Up to $242.5 million contingent on achieving specific milestones, including regulatory approval.
- Sales Milestones: Up to $375 million contingent on BMS achieving certain annual worldwide net sales thresholds.
- Royalties: Tiered royalties on annual worldwide net sales ranging from high single-digit to high-teen percentages (weighted average), subject to reductions based on specific metrics or sales thresholds.
- Financial Impact: The filing does not provide current revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes and Operational Updates
- Agreement Structure: BMS exercised its IND Option for PRX019. Instead of a U.S. License Agreement, the parties entered into a Global License Agreement granting BMS exclusive rights to develop, manufacture, and commercialize PRX019 globally.
- Research Term Expiration: The research term under the existing Master Collaboration Agreement expired on May 24, 2024.
- Clinical Trial Obligations: Prothena is obligated to run the Phase 1 clinical trial for PRX019, though BMS retains the option to take over this trial.
Outlook, Risks, and Contingencies
- Future Payments: Future milestone and royalty payments are contingent upon successful development, regulatory approval, and commercial sales performance.
- Payment Reductions: Milestones and royalties may be reduced if BMS develops a modified version of PRX019 with improved metrics or based on specific agreement terms.
- Termination Rights: Either party may terminate for uncured material breach or bankruptcy. BMS may terminate for safety reasons; Prothena may terminate for patent challenges by BMS.
- Term Duration: The agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable Royalty Terms (patents, regulatory exclusivity, or agreed post-sale periods).
Investor Verification Checklist
- Verify the receipt and accounting treatment of the $80 million upfront payment in the upcoming Form 10-Q for the quarter ending June 30, 2024.
- Review the full text of the PRX019 Global License Agreement (to be filed as an exhibit to the 10-Q) for specific definitions of "improved metrics" that could reduce future payments.
- Monitor the status of the Phase 1 clinical trial for PRX019 and any potential exercise by BMS to take over the trial.
- Confirm the specific tiered royalty percentages and sales thresholds in the full agreement text.